Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents <i>In Vitro</i> and <i>In Vivo</i>
Molecular cancer therapeutics